RxDoctor Payments Data

Marjolyne Sales

Family · Paramount, CANPI 1942661772

Payments from drug & device makers

$6,161in general payments, 2019–2025

Across 250 payments — averaging $24.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$989
  • AstraZeneca$838
  • Novo Nordisk$675
  • Lilly USA, LLC$547
  • Boehringer Ingelheim$535
  • Boston Scientific$462
  • plus $2K from 26 others

What the payments were for

  • Food & beverage$6,161100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,161 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.

See all family providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin29$47,982
OzempicSemaglutide37$43,385
TrulicityDulaglutide21$31,361
MounjaroTirzepatide12$25,615
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$20,503
Repatha SureclickEvolocumab16$14,744
Praluent PenAlirocumab11$8,651
Lantus SolostarInsulin Glargine,hum.Rec.Anlog30$3,122
Rosuvastatin Calcium63$1,289
Atorvastatin Calcium132$1,049
Albuterol Sulfate HfaAlbuterol Sulfate47$870
Levothyroxine Sodium40$580
Ezetimibe15$536
Pioglitazone Hcl37$491
Metformin Hcl69$463

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$547$56,97733 claims
Boehringer IngelheimJardiance$535$47,98229 claims
Novo NordiskOzempic$675$43,38537 claims
GSKTrelegy Ellipta$369$20,50321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.

Other family in Paramount

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →